objeCtives: There is a growing need to consider heterogeneity in cost-effectiveness analyses (CEA). To capture heterogeneity, subgroups analyses have been performed using various socio-demographic and clinical variables. However, the results of these subgroups CEA can be considered inequitable. Consequently, there is need to find new subgroups that can be used for decision-making. Methods: We explore whether subgroups defined by care-seeking behaviors are good candidates for CEA subgroup analysis. Care-seekers are defined as patients who received both an early diagnosis and an early treatment. We use data from the PLASA study, a French randomized controlled trial designed to reduce the rate of functional decline in Alzheimer's disease: 1,131 patients were randomized in an intervention group and in a control group and were followed during a 2-year period. We use a sample selection model to explore whether the unobserved heterogeneity associated with the early diagnosis decision is correlated with the unobserved heterogeneity associated with the early treatment decision. We use a fixed-effect model to explore whether the rate of functional decline was lower within the care-seekers subgroup. Results: Our theoretically grounded selection model shows that the care-seeking behavior is associated with unobserved preferences, motivating the need to run subgroup analyses within a subgroup of care-seekers. Our fixed-effect model results show that on average, the clinical intervention was not effective. However, the intervention was effective within the subgroup of care-seekers. Care-seekers who received the intervention did not face a significant decline in their functional status over the 2-year study period. On the contrary, care-seekers in the control group lost on average 9 points of ADCS-ADL per year (p< 0.01). ConClusions: Stratifying CEAs by care-seekers subgroups seems relevant. Our analyses can be easily implemented by adding three questions in the clinical protocol. objeCtives: To identify groups of countries with similar health preferences. Methods: Cluster analyses were performed for the 242 states of the general population EQ-5D valuations for 13 published studies based on Time Trade Off; and for 10 studies based on the Visual Analogue Scale. The perfect health state was not included. Cluster and their optimal number were identified by means of the Ward algorithm with the Euclidean measure and the hierarchical clustering technique. The identified clusters in each case are compared in order to find out whether they coincide. Results: 3 clusters were identified for TTO: 1) Germany, Argentina, Poland, The Netherlands, Denmark; 2) Japan, South Korea, USA, Hispanic USA, Zimbabwe; 3) Spain, Chile, UK. 4 clusters were identified for VAS: 1) Belgium, New Zealand, Germany; 2) Europe, UK, Spain; 3) Denmark, Slovenia; 4) Finland, Argentina. Countries are not in the same clusters for the two methodologies. Only the UK and Spain belong in the same groups in both cases. ConClusions: Healthstate valuations tend to be clustered in a few groups of countries but the groups differ according to the methodology. This suggests that Visual Analogue Scale results may not be a good approximation to Time Trade Off.
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iMtA PRoductivity cost QuestionnAiRe (iPcQ) objeCtives: Productivity costs often reflect a large part of the total cost in economic evaluations adopting a societal perspective. Currently, no consensus exists on how productivity losses are best measured. We aimed to develop a standardized instrument for measuring productivity losses to enhance the comparability and generalizability of the outcomes of economic evaluations. Methods: A focus group of well-experienced researchers in the field of measuring and valuing productivity losses for use in economic evaluations assessed the instruments' main quality criteria including: building on pre-knowledge and evidence on items' reliability and validity, inclusion of all relevant domains of productivity losses, allowing for quantifying productivity losses suitable for self-report. A feasibility study was performed to check on consistency and intelligibility of the questionnaire and applicability for different valuation methods. Results: The focus group identified three separate aspects of productivity losses leading to three modules in the iPCQ. Questions for measuring absenteeism and presenteeism are evidence-based originating from the Short-Form Health & Labour Questionnaire and PRODISQ. As evidence regarding measurement of losses of unpaid work is lacking, the questions of this module were developed during brainstorm sessions, based on similar questions on paid work. To enhance the instruments' feasibility and responsiveness the draft version was translated into language level 1 by an agency specialized in language and clear writing. The feasibility study included 195 respondents aged > 18 years. Five percent identified problems while filling in the iPCQ, including the questionnaire's instructions and routing (n= 8) and wording (n= 2). ConClusions: The iPCQ is based on previously available instruments and satisfies the current scientific state of play in productivity cost measurement and valuation. The instrument is understandable for the vast majority of the general public including low-educated people. To enhance the applicability of the iPCQ for national and international studies a translation in English is performed.
PRM40 feAsibility of the heAdRooM AnAlysis in eARly econoMic evAluAtion of innovAtive diAgnostic technologies with no iMMediAte tReAtMent iMPlicAtions
Van Nimwegen K. J.
Radboud university medical center, Nijmegen, The Netherlands
objeCtives: There is a growing need for early evaluation of innovative technologies to prevent ineffective and expensive technologies to be widely diffused in health care. The headroom method was introduced for early determination of the potential value of new technologies. In this study we explore the feasibility and usefulness of the headroom method in the early assessment of diagnostic technologies with no immediate treatment implications. Methods: We applied the headroom method to the implementation of whole exome sequencing (WES) into the current diagnostic trajectory of complex pediatric neurology. We determined the room for improvement regarding health-related quality of life (HRQoL), diagnostic yield and the duration of the current diagnostic trajectory. Results: The headroom in a certain diagnostic trajectory can be calculated after the so-called effectiveness gap is established and monetised. The preferred measure for the effectiveness gap is HRQoL expressed in quality-adjusted life years (QALYs). Since the direct product of diagnostics is information, and not improved health, no impact on HRQoL is expected. Other measures, such as diagnostic yield, can also be used to calculate the effectiveness gap. Unlike QALYs, these appeared difficult to monetise, however. Despite this difficulty, effectiveness gap calculation using these effect measures is very informative on the room for improvement in current clinical practice. In combination with foreseeable downstream costs and savings due to a new technology it gives an idea of the potential societal value of this technology. ConClusions: Despite some methodological challenges, the headroom method proved to be potentially useful in early health economic evaluation of diagnostic technologies with no immediate treatment implications. objeCtives: Bronchiectasis (BE) is characterised by permanent dilation of bronchi with destruction of elastic and muscular components of their walls. Prophylactic antibiotic treatment with acute management of exacerbation episodes is an important component of treatment. Currently there are no approved therapies for BE and inhaled antibiotics and nebulized solutions are used off-label. The objective of this study was to predict clinical and economic consequences associated with BE in adult patients over their lifetime. Methods: We developed a Markov cohort model with a cycle length of 4 weeks from UK health care perspective. The model included 4 Markov states: one stable disease state defined as confirmed non -cystic fibrosis bronchiectasis and without exacerbations in the previous 4 weeks and three exacerbation states defined on the basis of severity of exacerbation and associated health care resource utilization. Disease state specific costs included costs of drugs, consultations/visits, diagnostic test/procedures, physiotherapy, emergency room visits and hospitalizations. Patient baseline characteristics, exacerbation rates and utilities were estimated from literature. Results: The model suggests that ability to reduce hospitalizations and limit impact on quality of life are the major value drivers. The model is also sensitive to baseline risk of exacerbations. A treatment for BE that results in 35% reduction in exacerbation rates and related hospitalizations may result in a reduction of 15.53 exacerbations and 3.23 hospitalizations per patient over lifetime. Reduction in number of hospitalization will result in fewer long-term complications, leading to reduction of 1 death per 600 patients over a period of 10 years. The treatment could result in reduction of medical cost by £10,777 and 0.11 QALY gain per patient over lifetime. ConClusions: Any health care intervention that could reduce the number of exacerbations and related hospitalizations in the BE patients can have significant beneficial impact on clinical outcomes, costs and quality of life.
PRM48 diffeRent stRAtegies foR lAtent tb AssessMent in PAtients undeRgoing Anti-tnf tReAtMent: An econoMic Model
Pierotti F. , Trieste L. , Turchetti G. Scuola Superiore Sant'Anna, Pisa, Italy objeCtives: Since treatment with biologics may reactivate latent TB, testing and prophylaxes before initiating therapy are mandatory. However, there is not a unique solution for the number and type of tests to be used for detecting the presence of TB, and for the definition of when prophylaxis should be prescribed. Which alternative should be preferred depends on the effectiveness of treatment and also on the cost associated. This methodological study aims to define a general economic model to assess different protocols for latent TB detection in patients undergoing anti-TNF treatment. Methods: A decision tree approach has been designed for comparing alternative protocols in terms of (a) expected costs of different strategies for latent TB assessment in patients undergoing anti-TNF treatment; b) the economic convenience of the prophylaxis therapy in presence of a negative chest X-ray. Uncertainty is expressed by the probability of being positive and negative to the tests. In the NHS perspective the model considers: costs of tests; costs of TB onsets for rheumatologic patients who undergo biologics; costs of extending anti TB prophylaxis also to false negative patients; costs related to 1-month biologic therapy delay because of prophylaxis; costs for adverse events therapy and/or test related. Indirect costs are also considered in the broader societal perspective. Results: Costs assessed are useful to choose the less costly alternatives. The comparison also considers the reduction of false negatives to the tests which do not follow prophylaxis while being affected by latent TB. ConClusions: The model, that can represent a useful tool both for clinical and health policy decision making, is a general one; it can be applied to any country by inserting the country specific epidemiological, clinical, and economical data, and to any anti-TNF drug, by using the specific biologic drugrelated risk factor. The aim of this study is to assess how cost-effectiveness analyses of personalized medicine approaches (PMA) can be efficiently designed by using a case study in the field of acute myeloid leukemia. Methods: The cost-effectiveness analysis of the PMA was performed in two steps. As a PMA often only causes a treatment change in a specified subgroup of the patients, the cost-effectiveness of the identified treatment change was estimated as a first step (restricted analyses). Subsequently, a full cost-effectiveness analysis was performed which included all patients and the costs of identifying the specified subgroup. The relationship between the full and restricted analyses was evaluated by varying different input parameters. Results: It was found that the full cost-effectiveness of a PMA approach could be described as a function of the (cost-) effectiveness of the treatment change in the specified subgroup, the costs of identifying the subgroup and the size of the subgroup. If no additional costs are associated with the identification of the subgroup, the incremental cost-effectiveness ratio (ICER) of the full analysis is identical to the ICER of the restricted analysis. Otherwise, the ICER objeCtives: Diabetic nephropathy (DN) is a progressive kidney disease that occurs in around 40% of patients with diabetes, and the recommended treatment is an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). Individuals' health-related quality of life (HRQoL) can be summarised by utility values, which reflect preferences for different health states, and are used in cost-utility analyses (CUAs). This literature review identified the utilities used in CUAs of ACEi/ARB treatment in patients with DN. Methods: A combined protocol was developed to identify CUAs of ACEi/ARB treatment in DN as well as studies that estimated utilities in DN (for a separate review). We searched electronic databases (MEDLINE, EMBASE, NHS EED, HEED, CEA Registry, EconLit, RePEc, HTA) from 1 January 2000 to 31 July 2013. Search results were assessed for relevance by two reviewers. For eligible CUAs, data extracted included health states with assigned utilities. Results: Of 5236 references identified from the combined search, 28 CUAs remained after review of titles/abstracts, and eight after full text review. The CUAs assessed treatment (ACEi n= 3; ARB n= 4; both n= 1) in patients with type 1 diabetes (n= 2), type 2 diabetes (n= 4) or unspecified diabetes (n= 2). Seven CUAs used a Markov model and one a decision-analysis tree. Health states in the models included microalbuminuria, proteinuria, nephropathy, end-stage renal disease (ESRD), non-ESRD, dialysis and transplant. ESRD was the most frequent, with utilities ranging 0.53-0.69 (n= 6). Utility data used in the models were sourced from a number of different studies. ConClusions: For CUAs of ACEi/ARB therapy in patients with DN, few health states were included, and there was variation in values for the same health state due to a range of different reference sources being used. It is important for future economic models of DN therapies that robust utility values are available for included health states.
PRM50 An efficient design foR cost-effectiveness studies of PeRsonAlized Medicine stRAtegies
PRM45
Modelling dePendence between disAbility stAtus And heAlth seRvice costs of PeoPle with RheuMAtoid ARthRitis in hungARy 
The main objective of this study is to estimate the impact of the level of functional status and disability on health service costs related to rheumatoid arthritis (RA) disease in Hungary. It is straightforward to think that higher disability implies higher costs, where the nature of the relationship is unclear. In order to explore the dependence structure a novel approach is proposed. Instead of fitting trend lines for the cost by regression methods the entire bivariate distribution was modelled. Methods: Health Assessment Questionnaire's disability index data were collected for 497 RA patients (with 2594 observations) treated in the Arthritis Center (AC) Buda Hospital of Hospitaller Brothers of St. John from 1st January 2005 to 31st July 2013. The same patients were also found in the database of National Health Insurance Fund Administration (NHIFA) and further parameters as e.g. relevant treatments and health service costs (in-and outpatient) were collected. After merging AC and NHIFA database the 2 dimensional patterns of the HAQindex measurements versus costs (sum of relevant costs in the following quarter year) become available for bivariate modelling. The ingredients were the empirical distribution of HAQ-index and quarter year cost, and some parametric copula families (elliptical or Archimedean) capturing the (possibly non-linear) dependence structure. The performance of the different model assumptions were compared by goodness-of-fit procedures. Results: The fitted bivariate distribution based on the best-performing dependence model are shown in the original "HAQ-index vs. cost" scale. The differences of average costs for low/medium/high HAQ-index values are summarized and the conditional distribution functions of costs are presented, respectively. ConClusions: It has been proved that there is a significant positive dependence between the disability status of RA and health service costs. The dependence cannot be considered as linear but this non-linearity can be tackled easily by using copula methods. objeCtives: To design a user-friendly cost calculator to estimate and project health care costs of patients diagnosed with hepatitis C virus (HCV) infection in Turkey. Methods: We used Visual Basic in a Microsoft Excel to program complicated models within an easy-to-use framework for providers and payers to calculate pharmacy costs for HCV patients in Turkey. The calculator, first, uses the starting year to the end year as an input. The user then enters prevalent and incident patient numbers. Medication types, medication names, prescription numbers per year and prescription costs per medication are also entered. The calculator allows combination therapies. Depending on response rates, rates of incident and prevalent patients and medications type, prescription rates from 2014 and forward (until 2020) can then be calculated and projected. The calculator can be used for any country as long as the inputs are available through literature from real-world or simulation studies. Results: We used a hypothetical example to project pharmacy costs in Turkey in 2014 and 2015. We assumed 10,000 patients in 2014 (20% were assumed to be treatment naïve) and expected 2,000 new patients in 2015. We assumed ribavirin and telaprevir combination therapy for 2014 treatment naïve patients, and peginterferon alfa-2a and ribavirin for prevalent patients. The response and treatment rates were assumed at 80% for patients who were eligible for treatment. The recurrence rate was assumed to be approximately 10% after treatment. Pharmacy costs for HCV were calculated at € 7 million in 2014 and approximately € 2 million in 2015, using these rates. ConClusions: The economic burden of HCV in Turkey is significant. A simple-to-use calculator that uses real-world data and econometric models to estimate health care costs of patients with HCV can help payers and providers to make improved evidence-based health care decisions.
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